Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig

Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig

NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB…

Nanjing Leads Biolabs Doses First Patient in Phase 1b/II Trial of PD-L1/4-1BB Bispecific Antibody for Melanoma

Nanjing Leads Biolabs Co., Ltd. announced that the firs […] The post Nanjing Leads Biolabs Doses First Patient in Phase 1b/II Trial of PD-L1/4-1BB Bispecific Antibody for Melanoma first appeared on GeneOnline News. The post Nanjing Leads Biolabs Doses First Patient in Phase 1b/II Trial of PD-L1/4-1BB Bispecific Antibody for Melanoma appeared first on GeneOnline News.